Medicine and Dentistry
Neoplasm
100%
Macrophage
86%
Melanoma
74%
Ovarian Cancer
57%
Immunoglobulin E Antibody
57%
Immunoglobulin E
51%
Melanoma Skin Cancer
34%
Tumor Microenvironment
33%
Monoclonal Antibody
32%
Malignant Neoplasm
31%
Immunocompetent Cell
29%
Clinician
28%
Folate Receptor 1
28%
Skin Manifestation
28%
Chemokine
28%
extracellular signal regulated kinase
28%
Monoclonal Antibody Therapy
28%
Immunosuppressive Drug
28%
Repolarization
28%
Cell Interaction
28%
Metastatic Carcinoma
11%
Cancer Cell
11%
Immunotherapy
11%
Tumor Antigen
10%
Immune Response
9%
Phase I Trials
9%
Immunosuppressive Treatment
8%
Tumor Progression
7%
Macrophage Polarization
7%
Cancer Growth
7%
Ovarian Tumor
7%
Adaptive Immunity
7%
Tryptase
7%
Infusion
7%
Skin Biopsy
7%
Gene Expression Profiling
7%
Basophil Cell
7%
Phenotypic Plasticity
7%
Fc Receptor
7%
Tumor-Associated Immunosuppression
7%
Tumor Cell
7%
Cellular Infiltration
7%
Clinical Study
6%
Mediator
6%
Experimental Therapy
5%
Cell Therapy
5%
Cytokine Release
5%
Survival Rate
5%
Angiogenesis Inhibitor
5%
Target Identification
5%
Immunology and Microbiology
Tumor-Associated Macrophage
86%
Monoclonal Antibody
66%
Macrophage
64%
Immunocompetent Cell
63%
Immunoglobulin E
57%
Immune Response
51%
Immunotherapy
42%
Immunoglobulin E Antibody
30%
Trastuzumab
28%
Gamma Urogastrone
28%
Monoclonal Antibody Therapy
28%
B Cell
28%
Immune Checkpoint Blockade
28%
Inflammatory Cytokine
28%
Angiogenesis Inhibitor
28%
Chondroitin Sulfate Proteoglycan
28%
Cytokine Release
28%
Survival Rate
28%
Chemokine
28%
Cancer Cell
20%
Cell Surface
11%
Basophil Activation
11%
Tumor Cell
11%
Adaptive Immune System
9%
Tumor Antigen
9%
Fc Receptor
9%
Angiogenesis
8%
T Cell
8%
Humoral Immunity
8%
Antibody Blood Level
8%
Tumor-Associated Immunosuppression
7%
Gene Expression Assay
7%
Phenotypic Plasticity
7%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
42%
Monoclonal Antibody
32%
Immunoglobulin E
28%
Melanoma
28%
Folate Receptor 1
28%
Skin Manifestation
28%
Immunoglobulin E Antibody
28%
Tumor Microenvironment
28%
Ovary Cancer
28%
Cytokine
13%
Target Identification
9%
Angiogenesis Inhibitor
9%
Survival Rate
9%
Cutaneous Melanoma
9%
Tumor Antigen
7%
Tryptase
7%